MCID: DYS009
MIFTS: 48

Dysthymic Disorder

Categories: Mental diseases

Aliases & Classifications for Dysthymic Disorder

MalaCards integrated aliases for Dysthymic Disorder:

Name: Dysthymic Disorder 12 43 15 17 71
Dysthymia 12 74 54 32

Classifications:



External Ids:

Disease Ontology 12 DOID:12139
ICD9CM 34 300.4
MeSH 43 D019263
NCIt 49 C34562
SNOMED-CT 67 78667006
ICD10 32 F34.1
UMLS 71 C0013415

Summaries for Dysthymic Disorder

Disease Ontology : 12 A mood disorder that involves the presence of a low mood almost daily over a span of at least two years.

MalaCards based summary : Dysthymic Disorder, also known as dysthymia, is related to neurotic disorder and depression. An important gene associated with Dysthymic Disorder is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Serotonergic synapse and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Methyltestosterone and Testosterone undecanoate have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and heart, and related phenotype is behavior/neurological.

Wikipedia : 74 Dysthymia, also known as persistent depressive disorder (PDD), is a mood disorder consisting of the same... more...

Related Diseases for Dysthymic Disorder

Diseases related to Dysthymic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 135)
# Related Disease Score Top Affiliating Genes
1 neurotic disorder 31.1 SLC6A4 MAOA HTR2A HTR1A BDNF
2 depression 30.9 SLC6A4 MAOA HTR2A HTR1A DISC2 BDNF
3 personality disorder 30.9 SLC6A4 MAOA HTR2A HTR1A BDNF
4 cyclothymic disorder 30.9 PIR HTR2A CGAS
5 avoidant personality disorder 30.8 WASF2 WASF1 SLC6A4 PIR MAOA
6 generalized anxiety disorder 30.7 SLC6A4 MAOA HTR2A HTR1A BDNF
7 major depressive disorder 30.6 SLC6A4 MAOA HTR2A HTR1A HCRT DISC2
8 mood disorder 30.4 SLC6A4 MAOA HTR2A HTR1A DISC2 BDNF
9 anxiety 30.3 SLC6A4 MAOA HTR2A HTR1A HCRT CFI
10 schizoid personality disorder 30.3 WASF2 WASF1 PIR
11 panic disorder 30.2 SLC6A4 MAOA HTR2A HTR1A BDNF
12 obsessive-compulsive disorder 30.2 SLC6A4 MAOA HTR2A HTR1A BDNF
13 separation anxiety disorder 30.2 WASF2 WASF1 SLC6A4 PROC DISC2 CGAS
14 attention deficit-hyperactivity disorder 30.2 SLC6A4 MAOA HTR2A HTR1A BDNF
15 chronic fatigue syndrome 30.1 SLC6A4 MAOA HTR2A HTR1A
16 cannabis abuse 30.1 WASF2 WASF1 HTR1A BDNF
17 bulimia nervosa 30.1 SLC6A4 MAOA HTR2A BDNF
18 alcohol use disorder 30.1 WASF2 WASF1 SLC6A4 HTR2A HTR1A BDNF
19 eating disorder 30.1 SLC6A4 HTR2A HCRT BDNF
20 somatization disorder 30.1 SLC6A4 SCLY IVL HTR2A HTR1A
21 bipolar i disorder 30.1 SLC6A4 HTR2A HTR1A BDNF
22 irritable bowel syndrome 30.0 SLC6A4 HTR2A HTR1A BDNF
23 atypical depressive disorder 30.0 SLC6A4 MAOA HTR2A HTR1A BDNF
24 melancholia 30.0 SLC6A4 MAOA HTR2A HTR1A BDNF
25 endogenous depression 30.0 SLC6A4 SCLY MAOA LIPA HTR2A HTR1A
26 borderline personality disorder 30.0 SLC6A4 MAOA HTR2A HTR1A BDNF
27 bipolar disorder 29.9 SLC6A4 MAOA HTR2A HTR1A DISC2 BDNF
28 mental depression 29.9 WASF2 WASF1 SLC6A4 SCLY PROC MAOA
29 alcohol dependence 29.9 SLC6A4 MAOA HTR2A HTR1A HCRT BDNF
30 sleep disorder 29.9 SLC6A4 HTR2A HTR1A HCRT BDNF
31 schizotypal personality disorder 29.8 WASF2 WASF1 PIR NT5M
32 dementia 29.7 MAOA HTR2A HTR1A HCRT BDNF
33 hypochondriasis 29.7 SLC6A4 PIR IVL HTR2A HTR1A BDNF
34 anorexia nervosa 29.7 SLC6A4 MAOA HTR2A HTR1A HCRT BDNF
35 schizophrenia 29.6 SLC6A4 MAOA HTR2A HTR1A HCRT DISC2
36 psychotic disorder 29.5 SLC6A4 MAOA HTR2A HTR1A CFI BDNF
37 obsessive-compulsive personality disorder 29.5 WASF2 WASF1 SLC6A4 PIR NT5M HTR2A
38 adjustment disorder 29.4 SLC6A4 SCLY HTR2A HCRT CGAS CFI
39 antisocial personality disorder 29.4 WASF2 WASF1 SLC6A4 PIR MAOA HTR2A
40 substance abuse 29.3 WASF2 WASF1 SLC6A4 PROC MAOA HTR2A
41 migraine with or without aura 1 29.3 SLC6A4 MAOA HTR2A HTR1A HCRT EHD4
42 social phobia 29.1 WASF2 WASF1 SLC6A4 MAOA IVL HTR1A
43 oppositional defiant disorder 28.9 WASF3 WASF2 WASF1 SLC6A4 PROC MAOA
44 phobia, specific 27.5 WASF2 WASF1 SLC6A4 PROC NT5M MAOA
45 tic disorder 10.4 SLC6A4 MAOA HTR2A
46 alcoholic psychosis 10.4 SLC6A4 HTR2A
47 cataract 25 10.4 WASF3 WASF1
48 dissociative disorder 10.4 SLC6A4 SCLY HTR2A
49 body dysmorphic disorder 10.3 SLC6A4 MAOA HTR2A
50 kleptomania 10.3 SLC6A4 MAOA HTR1A

Comorbidity relations with Dysthymic Disorder via Phenotypic Disease Network (PDN): (show top 50) (show all 52)


Active Peptic Ulcer Disease Acute Cystitis
Adjustment Disorder Anxiety
Atrophic Gastritis Atypical Depressive Disorder
Avoidant Personality Disorder Benign Essential Hypertension
Borderline Personality Disorder Bronchitis
Chronic Pulmonary Heart Disease Conversion Disorder
Deficiency Anemia Delusional Disorder
Dependent Personality Disorder Dyskinesia of Esophagus
Esophagitis Familial Atrial Fibrillation
Generalized Anxiety Disorder Generalized Atherosclerosis
Heart Disease Histrionic Personality Disorder
Hypertension, Essential Hypochondriasis
Hypothyroidism Intermediate Coronary Syndrome
Iron Deficiency Anemia Irritable Bowel Syndrome
Major Depressive Disorder Mitral Valve Disease
Mood Disorder Narcissistic Personality Disorder
Obsessive-Compulsive Disorder Obsessive-Compulsive Personality Disorder
Opioid Addiction Oral Candidiasis
Osteoarthritis Osteoporosis
Paralytic Ileus Parkinson Disease, Late-Onset
Peripheral Vascular Disease Personality Disorder
Postinflammatory Pulmonary Fibrosis Post-Traumatic Stress Disorder
Postural Orthostatic Tachycardia Syndrome Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder
Social Phobia Somatization Disorder

Graphical network of the top 20 diseases related to Dysthymic Disorder:



Diseases related to Dysthymic Disorder

Symptoms & Phenotypes for Dysthymic Disorder

MGI Mouse Phenotypes related to Dysthymic Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.36 BDNF CGAS HCRT HTR1A HTR2A LIPA

Drugs & Therapeutics for Dysthymic Disorder

Drugs for Dysthymic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyltestosterone Approved Phase 4 58-18-4 6010
2
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
3
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 6013 10204
4
Testosterone enanthate Approved Phase 4 315-37-7 9416
5
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
6
Imipramine Approved Phase 4 50-49-7 3696
7
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
8
Sodium citrate Approved, Investigational Phase 4 68-04-2
9
Memantine Approved, Investigational Phase 4 19982-08-2 4054
10
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
11
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
12
Donepezil Approved Phase 4 120014-06-4 3152
13
Citalopram Approved Phase 4 59729-33-8 2771
14
Norepinephrine Approved Phase 4 51-41-2 439260
15
Sertraline Approved Phase 4 79617-96-2 68617
16
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
17
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
18 Anabolic Agents Phase 4
19 Antineoplastic Agents, Hormonal Phase 4
20 Hormone Antagonists Phase 4
21 Testosterone 17 beta-cypionate Phase 4
22 Hormones Phase 4
23 Androgens Phase 4
24 Desvenlafaxine Succinate Phase 4 386750-22-7
25 Monoamine Oxidase Inhibitors Phase 4
26 Antidepressive Agents, Tricyclic Phase 4
27 Venlafaxine Hydrochloride Phase 4
28 Cytochrome P-450 CYP3A Inducers Phase 4
29 Anticoagulants Phase 4
30 Citrate Phase 4
31 Chelating Agents Phase 4
32 Sildenafil Citrate Phase 4 171599-83-0
33 Phosphodiesterase 5 Inhibitors Phase 4
34 Vasodilator Agents Phase 4
35 Calcium, Dietary Phase 4
36 Phosphodiesterase Inhibitors Phase 4
37 Excitatory Amino Acid Antagonists Phase 4
38 Excitatory Amino Acids Phase 4
39 Nootropic Agents Phase 4
40 Cholinesterase Inhibitors Phase 4
41 Cholinergic Agents Phase 4
42 Autonomic Agents Phase 4
43 Cholinergic Antagonists Phase 4
44 Antiparkinson Agents Phase 4
45 Muscarinic Antagonists Phase 4
46 Parasympatholytics Phase 4
47 Analgesics Phase 4
48 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
49 Duloxetine Hydrochloride Phase 4
50
Mirtazapine Approved Phase 2, Phase 3 85650-52-8, 61337-67-5 4205

Interventional clinical trials:

(show top 50) (show all 107)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Testosterone Replacement in Treating Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Unknown status NCT00260390 Phase 4 Testoviron
2 Double-Blind Treatment of Outpatients With Dysthymic Disorder With Wellbutrin XL Completed NCT00225251 Phase 4 bupropion XL
3 Duloxetine for Chronic Depression: a Double-blind Study Completed NCT00360724 Phase 4 Duloxetine (Cymbalta)
4 An Open Treatment Trial of Duloxetine in Elderly Patients With Dysthymic Disorder Completed NCT01852383 Phase 4 Duloxetine
5 Combined Escitalopram/Bupropion as First Line Treatment for Depression, a Replication. Completed NCT00296712 Phase 4 escitalopram + bupropion
6 Desvenlafaxine (Pristiq) vs. Placebo in the Treatment of Chronic Depression Completed NCT01537068 Phase 4 Desvenlafaxine;Placebo
7 Medication Treatment Following Neuropsychologic, Dichotic and f-MRI Tests in Depressed Outpatients With Repeat f-MRI Following Treatment Completed NCT00296777 Phase 4 Escitalopram;Bupropion;Imipramine
8 Double-Blind Placebo-Controlled Study of Escitalopram in the Treatment of Dysthymic Disorder Completed NCT00220701 Phase 4 Lexapro (escitalopram)
9 A Controlled Trial of Venlafaxine XR for Major Depression After Spinal Cord Injury: A Multi-site Study Completed NCT00592384 Phase 4 venlafaxine XR;placebo
10 Escitalopram vs. Sertraline in the Treatment of Dysthymic Disorder and Double Depression Completed NCT00234312 Phase 4 escitalopram and sertraline
11 Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Major Depressive Disorder or Dysthymic Disorder Completed NCT00518986 Phase 4 armodafinil;placebo
12 A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression Completed NCT00296699 Phase 4 Duloxetine
13 A Multi-Center, Flexible Dose Study With A Double-Blind, Randomized, Placebo-Controlled Phase Followed By An Open-Label Phase To Evaluate The Impact Of Treatment With Sildenafil Citrate On The Symptoms Of Depression And Quality Of Life (Qol) Of Male Patients With Erectile Dysfunction (ED) Completed NCT00159809 Phase 4 Viagra (Sildenafil citrate)
14 Attenuation of Corticosteroid Induced Hippocampal Changes Completed NCT01656187 Phase 4 Memantine 10 mg capsule;Memantine-matched Placebo capsule
15 Antidepressant Treatment at an Inner City Asthma Clinic Completed NCT01324700 Phase 4 High severity group: Escitalopram;High severity group: Placebo;Low severity group: Escitalopram;Low severity group: Placebo
16 Pilot Combination Treatment Trial of Mild Cognitive Impairment With Depression Completed NCT01658228 Phase 4 Donepezil;Placebo;Citalopram;Venlafaxine
17 Single-Site, Double-Blind, Flexible-Dose, Placebo-Controlled Study of the Efficacy, Tolerability, & Safety of Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
18 Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults Active, not recruiting NCT01973283 Phase 4 Antidepressant Medication
19 Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction Terminated NCT00398632 Phase 4 Duloxetine
20 Sertraline in the Treatment of Generalized Social Phobia With Comorbidity Terminated NCT00182533 Phase 4 Sertraline;Placebo
21 A Comparison of Medication Augmentation and Problem Solving Therapy Withdrawn NCT01942187 Phase 4 Aripiprazole;Bupropion
22 Efficacy and Cost-Effectiveness of 18-Months of Antidepressive Medication Plus Either Cognitive-Behavior Therapy or Dynamic Psychotherapy Compared to Supportive Clinical Management for Recurrent Major Depression: a Pilot Study Unknown status NCT00220623 Phase 3 antidepressant medications, flexible drug choice
23 A Stepped Care Model of Adolescent Depression Treatment in Primary Care Completed NCT01443715 Phase 2, Phase 3
24 An Open Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior Completed NCT01447602 Phase 3
25 Treatment of Adolescent Suicide Attempters (TASA) Completed NCT00080158 Phase 2, Phase 3 fluoxetine;sertraline;citalopram;escitalopram;bupropion;mirtazapine;venlafaxine;lithium
26 A Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 in Subjects With Major Depressive Disorder Completed NCT00707980 Phase 3 Vortioxetine
27 Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment Completed NCT01876823 Phase 2, Phase 3 es-citalopram;Memantine
28 A Proof of Concept Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders Completed NCT01979133 Phase 3 Icariin
29 A Single-Blind Prospective Study of Quetiapine for the Treatment of Mood Disorders in Adolescents Completed NCT00221468 Phase 3 quetiapine
30 ASCEND: A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression Completed NCT02358343 Phase 3 Antidepressant Drug Therapy
31 A Pilot Study -- An Open-Label, Rater-blinded, Flexible-dose, 8-week Trial of Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features. Completed NCT00610506 Phase 3 Escitalopram
32 A Phase 3 Double Blind, Randomized, Placebo Controlled, Cross-Over Trial to Asses the Efficacy of CALPXT96™in Improving Sleep Quality in Patients With Chronic Non-cancer Pain Withdrawn NCT02232256 Phase 3 CALPXT96
33 Dichotic Listening as a Predictor of Placebo and Medication Response in Depression Completed NCT00296725 Phase 1, Phase 2 Fluoxetine;Imipramine
34 Group IPT for Women Prisoners With Comorbid Substance Use and Depression Completed NCT00606996 Phase 2
35 The Efficacy of Parent Involvement in the Treatment of Adolescent Depression Completed NCT00883519 Phase 1, Phase 2
36 Engagement and Alliance in CBT for Depressed Adolescents Completed NCT00073359 Phase 1, Phase 2
37 A Double-Blind, Placebo-Controlled Study Examining The Safety, Efficacy, and Tolerability of SEP-225289 in Subjects With Major Depressive Disorder (Including Atypical and Melancholic Features) Completed NCT00584974 Phase 2 SEP-225289;SEP-225289;Venlafaxine;placebo
38 Group Interpersonal Psychotherapy for Depressed Adolescents (IPT-AG) in School-based Clinics Completed NCT00270244 Phase 2
39 New Approaches to Cocaine Abuse Medications (A) Completed NCT00000271 Phase 2 Desipramine;Placebo
40 Bringing What Works to Youth in Prison: An Evidence-Based Trauma Intervention Completed NCT01560728 Phase 1, Phase 2
41 A Phase 2a Study to Evaluate the Kappa Opioid Receptor As a Target for the Treatment of Mood and Anxiety Spectrum Disorders by Evaluation of Whether CERC-501 Engages Key Neural Circuitry Related to the Hedonic Response Completed NCT02218736 Phase 2 CERC-501;placebo
42 Effectiveness of Team Treatment of Depression in Primary Care Completed NCT00012766 Phase 2
43 Computerized Information-Processing Bias Retraining in Adolescents With Depression: A Controlled Trial Completed NCT01147913 Phase 2
44 eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients Active, not recruiting NCT02458690 Phase 2 Antidepressant Medications
45 Smoking Cessation Intervention for Depressed Smokers: Treatment Development Active, not recruiting NCT00494728 Phase 1, Phase 2 Nicotine Replacement Therapy
46 TRIAD Project: Pennsylvania Adolescent Intervention Research Study (PAIRStudy; Project 3a) Terminated NCT00329199 Phase 2
47 A Single-blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks Terminated NCT00206765 Phase 2 Risperidone;Paroxetine
48 An Open Clinical Trial of Interpersonal Psychotherapy for Depressed Adolescence and Parents Completed NCT00619411 Phase 1
49 Treatment of Women With Depression and Sexual Abuse Completed NCT00042237 Phase 1
50 Omega-3 Fatty Acids & Psychoeducational Psychotherapy for Childhood Depression Completed NCT01341925 Phase 1 Omega-3 Supplementation

Search NIH Clinical Center for Dysthymic Disorder

Cochrane evidence based reviews: dysthymic disorder

Genetic Tests for Dysthymic Disorder

Anatomical Context for Dysthymic Disorder

MalaCards organs/tissues related to Dysthymic Disorder:

40
Testes, Brain, Heart, Breast, Spinal Cord, Eye, Thyroid

Publications for Dysthymic Disorder

Articles related to Dysthymic Disorder:

(show top 50) (show all 2714)
# Title Authors PMID Year
1
Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. 61 54
17346943 2007
2
5-HT2A and 5-HT2C receptors and their atypical regulation properties. 54 61
12650852 2003
3
Dysthymia: clinical picture, extent of overlap with chronic fatigue syndrome, neuropharmacological considerations, and new therapeutic vistas. 61 54
10357046 1999
4
Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group. 61 54
9347378 1997
5
Moclobemide versus fluoxetine for double depression: a randomized double-blind study. 54 61
9023788 1996
6
Studies of reversible and selective inhibitors of monoamine oxidase A in dysthymia. 61 54
7717093 1995
7
5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. 61 54
1903019 1991
8
Prevalence and recognition of depressive disorders among Chinese older adults receiving primary care: A multi-center cross-sectional study. 61
31493635 2020
9
Correction to: Factors Associated with Mood Disorder Diagnosis Among a Population Based Cohort of Men and Women Living With and Without HIV in British Columbia Between 1998 and 2012. 61
31820184 2019
10
Anxiety and Depression in Patients with Obstructive Sleep Apnoea before and after Continuous Positive Airway Pressure: The ADIPOSA Study. 61
31805748 2019
11
Convergence of psychiatric symptoms and restless legs syndrome: A cross-sectional study in an elderly French population. 61
31794908 2019
12
Evaluation of neuropsychiatric comorbidities and their clinical characteristics in Chinese children with asthma using the MINI kid tool. 61
31752780 2019
13
Effectiveness and Safety of Bupropion in Children and Adolescents with Depressive Disorders: A Retrospective Chart Review. 61
31671492 2019
14
Depression predicts self assessment of social function in both patients with schizophrenia and healthy people. 61
31740212 2019
15
The prevalence of comorbid depression in patients with diabetes: A meta-analysis of observational studies. 61
31790965 2019
16
Validation of the Recent Life Changes Questionnaire (RLCQ) for stress measurement among adults residing in urban communities in Pakistan. 61
31639054 2019
17
A machine learning ensemble to predict treatment outcomes following an Internet intervention for depression. 61
30392475 2019
18
Current pharmacotherapeutic approaches for dysthymic disorder and persistent depressive disorder. 61
31290333 2019
19
Lifestyle interventions for mental health. 61
31569326 2019
20
Sociodemographic Characteristics of Adult Saudi Patients with Mood Disorder Subtypes. 61
31543738 2019
21
Post-traumatic stress reactions among individuals with visual impairments: a systematic review. 61
29644887 2019
22
Factors associated with tobacco consumption in patients with depression. 61
31018000 2019
23
Depressive role impairment and subthreshold depression in older black and white women: race differences in the clinical significance criterion. 61
31455459 2019
24
Construction of Disease Similarity Networks Using Concept Embedding and Ontology. 61
31437962 2019
25
[Epidemiological survey of mental disorders in the rural left behind elderly aged 60 years and older in Gansu]. 61
31434422 2019
26
Prevalence of Psychiatric Disorders and Associated Factors among the Youth in Ravansar, Iran. 61
31679346 2019
27
Changes in the global burden of depression from 1990 to 2017: Findings from the Global Burden of Disease study. 61
31439359 2019
28
Fibromyalgia and its New Lessons for Neuropsychiatry. 61
31273184 2019
29
Is the association between precarious employment and mental health mediated by economic difficulties in males? Results from two Italian studies. 61
31269944 2019
30
Toward a neurobehavioral trait conceptualization of depression proneness. 61
30950526 2019
31
Minding the treatment gap: results of the Singapore Mental Health Study. 61
31317246 2019
32
Amisulpride as an Augmentation Agent in Treatment Resistant Depression: A Case Series and Review of the Literature. 61
31291218 2019
33
Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults. 61
31106850 2019
34
Effects of stigmatizing media coverage on stigma measures, self-esteem, and affectivity in persons with depression - an experimental controlled trial. 61
31064374 2019
35
Facets of Mindfulness in Adults with Generalized Anxiety Disorder and Impact of Co-occurring Depression. 61
31360261 2019
36
Adjunctive Internet-delivered cognitive behavioural therapy for insomnia in men with depression: A randomised controlled trial. 61
30191722 2019
37
Tracking the mental health of a nation: prevalence and correlates of mental disorders in the second Singapore mental health study. 61
30947763 2019
38
Incident Chronic Spinal Pain and Depressive Disorders: Data From the National Comorbidity Survey. 61
30471429 2019
39
Efficacy of an internet-based self-management intervention for depression or dysthymia - a study protocol of an RCT using an active control condition. 61
30871544 2019
40
Extremism and common mental illness: cross-sectional community survey of White British and Pakistani men and women living in England. 61
30873926 2019
41
Effect of early supported discharge after stroke on patient reported outcome based on the Swedish Riksstroke registry. 61
30866844 2019
42
The Role of Self-Esteem in Depression: A Longitudinal Study. 61
29692278 2019
43
A study of psychiatric morbidity among school going adolescents. 61
30992616 2019
44
ADHD: a hidden comorbidity in adult psychiatric patients. 61
30927233 2019
45
Screening for depressive and anxiety disorders among adolescents in Indonesia: Formal validation of the centre for epidemiologic studies depression scale - revised and the Kessler psychological distress scale. 61
30583144 2019
46
The concurrent validity of a Web-based self-report assessment for personality disorders. 61
30592174 2019
47
A study on the association of psychiatric diagnoses and childhood adversities with suicide risk. 61
30856038 2019
48
The impact of depressive comorbidity on neural plasticity following cognitive-behavioral therapy in panic disorder with agoraphobia. 61
30428445 2019
49
Lifetime experience of multiple common mental disorders and 19-year mortality: results from a Canadian population-based cohort. 61
30712520 2019
50
Defining cognitive profiles of depressive patients using the Brief Assessment of Cognition in Affective Disorders. 61
31396459 2019

Variations for Dysthymic Disorder

Expression for Dysthymic Disorder

Search GEO for disease gene expression data for Dysthymic Disorder.

Pathways for Dysthymic Disorder

GO Terms for Dysthymic Disorder

Cellular components related to Dysthymic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 SCAR complex GO:0031209 8.62 WASF2 WASF1

Biological processes related to Dysthymic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 memory GO:0007613 9.5 SLC6A4 HTR2A BDNF
2 Rac protein signal transduction GO:0016601 9.43 WASF2 WASF1
3 temperature homeostasis GO:0001659 9.4 HTR2A HCRT
4 vasoconstriction GO:0042310 9.37 SLC6A4 HTR1A
5 sleep GO:0030431 9.26 HTR2A HCRT
6 behavior GO:0007610 9.16 HTR2A HTR1A
7 negative regulation of potassium ion transport GO:0043267 8.96 HTR2A HCRT
8 serotonin receptor signaling pathway GO:0007210 8.62 HTR2A HTR1A

Molecular functions related to Dysthymic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serotonin binding GO:0051378 8.8 SLC6A4 HTR2A HTR1A

Sources for Dysthymic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....